Facebook
Twitter
LinkedIn
Forward
Innervation Innovation: New Insights on the Role of Corneal Nerves in Ocular Surface Diseases (CME/CE Monograph)
Activity Description and Purpose
Corneal nerves play an essential role in the preservation of optimal ocular health. Alterations of the delicate balance of homeostatic and sensory functions of corneal nerves result in the pathogenesis of several ocular surface diseases, including dry eye disease, neurotrophic keratitis, and neuropathic corneal pain. This educational activity will explore the role of the structural and functional integrity of corneal nerves in ocular health preservation and review the pathogenesis of disease contributing to corneal nerve dysfunction. Some of the current and future therapeutic options for the prevention and management of corneal nerve dysfunction in ocular surface disease will also be reviewed.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the role of corneal sensory innervation in ocular surface health
- Identify disease characteristics that portend to impaired or damaged corneal nerve innervation
Faculty
 | Kendall E. Donaldson, MD, MS (Co-Chair) |
 | Douglas K. Devries, OD (Co-Chair) |
 | Jaclyn Garlich, OD |
 | Pedram Hamrah, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Douglas K. Devries, OD, is a consultant for Alcon, Allergan, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, and Visus Therapeutics; and is on the speakers bureau of Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Kendall E. Donaldson, MD, MS, is a consultant for AcuFocus, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Omeros Corporation, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.
Jaclyn Garlich, OD, is a consultant for Lumenis; and is an advisory board member of Allergan, Bruder Healthcare, Dompé US, Inc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited.
Pedram Hamrah, MD, is a consultant for Kala Pharmaceuticals and Santen Inc; is an advisory board member of Dompé US, Inc, Hawkeye Therapeutics, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, and Oyster Point Pharma, Inc; and is a contracted researcher for Claris Biotherapeutics, CooperVision, Dompé US, Inc, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, Ocular Therapeutix, Inc, OKYO Pharma, Limited, and Oyster Point Pharma, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 85009-TD
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 126328, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, State University of New York College of Optometry, or Dompé US, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 266.1
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 COPE
- 1.00 Participation